Epstein-Barr virus-related tumor
MONDO:0017342Also known as: EBV-related tumor, EBV-related tumour
2411 clinical trials for this condition and its sub-types, 8 tagged with Epstein-Barr virus-related tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Epstein-Barr virus-related tumor
-
Epstein-Barr virus-associated lymphoproliferative disorder 22 trials · 713 incl. sub-types
11 sub-types
- Hodgkins lymphoma 262 trials · 326 incl. sub-types Sub-types →
- Burkitt lymphoma 221 trials Sub-types →
- Primary central nervous system lymphoma 92 trials · 103 incl. sub-types Sub-types →
- Extranodal nasal NK/T cell lymphoma 51 trials
- Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly 23 trials
- Plasmablastic lymphoma 20 trials
- Primary effusion lymphoma 18 trials
- Lymphomatoid granulomatosis 3 trials · 7 incl. sub-types Sub-types →
- Diffuse large B-cell lymphoma with chronic inflammation 3 trials
- Hydroa vacciniforme-like lymphoma 3 trials
- Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood 2 trials
-
Epstein-Barr virus-associated carcinoma 2 trials · 214 incl. sub-types
3 sub-types
- Nasopharyngeal carcinoma 211 trials · 212 incl. sub-types Sub-types →
- Epstein-Barr virus-associated gastric carcinoma 1 trial
- Lymphoepithelial-like carcinoma 1 trial
-
Epstein-Barr virus-associated mesenchymal tumor 1 trial · 75 incl. sub-types
3 sub-types
- Leiomyosarcoma 62 trials · 72 incl. sub-types Sub-types →
- Follicular dendritic cell sarcoma 2 trials
- Myopericytoma 0 trials
Most studied deeper sub-types
-
New cell therapy targets Epstein-Barr virus in immune-compromised patients
Disease control OngoingThis study tests an experimental cell therapy called tabelecleucel in 190 people with diseases caused by the Epstein-Barr virus (EBV), including certain lymphomas and post-transplant complications. The treatment uses specially prepared immune cells to fight the virus. The main go…
Phase 2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug targets virus to fight rare cancer
Disease control OngoingThis phase 2 trial tests a drug called VK-2019 in 13 patients with Epstein-Barr virus (EBV)-positive nasopharyngeal cancer that has returned or spread and has no standard treatment. VK-2019 works by blocking a key viral protein, EBNA1, which the virus needs to survive. The main g…
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Experimental immune therapy targets EBV-Linked cancers in early trial
Disease control OngoingThis early-stage study tests a new immune-based treatment for people with advanced cancers linked to the Epstein-Barr virus (EBV) who have not responded to standard therapies. Only 6 participants are enrolled to check if the treatment is safe and to get a first look at whether it…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC